SimplyTest Oral Health Launches Implant-Specific Salivary Test
With SimplyTest Oral Health-IMPLANT, clinicians now have a fast, noninvasive way to identify the microbial risks before failure occurs. It's another step forward in our mission to elevate patient care through precision-based oral health solutions.
According to a comprehensive review published in Cureus in 2022, infection is the most frequent and preventable cause of dental implant failure. SimplyTest Implant is engineered to detect eight high-risk pathogens, which include Porphyromonas gingivalis (Pg), Treponema denticola (Td), Tannerella forsythia (Tf), Prevotella intermedia (Pi), Fusobacterium nucleatum (Fn), Fusobacterium animalis (Fa), Candida albicans (Ca) and Pseudomonas aeruginosa (Pa). These organisms are recognized contributors to inflammation, tissue degradation and systemic immune response, often without visible early symptoms.
'Microbial infections are a major cause of implant-related complications,' said Joel Peek, Ph.D., SimplyTest Founder and Scientific Advisory Board Chair. 'With SimplyTest Oral Health-IMPLANT, clinicians now have a fast, noninvasive way to identify the microbial risks before failure occurs. It's another step forward in our mission to elevate patient care through precision-based oral health solutions.'
Designed for chairside use or at-home collection, IMPLANT leverages a proprietary saliva preservation and analysis system. Results are delivered within 24 to 48 hours after the sample is received at the lab via a secure clinical portal, with pathogen-specific insights to support diagnostic conversations and treatment planning.
'The SimplyTest Oral Health line is part of a broader effort to redefine the standard of care in dentistry and systemic healthcare by empowering providers with tools that reveal the root causes of oral and systemic conditions,' said Justin Hunt, CEO of Spectrum Health Science. 'The IMPLANT test expands our platform's reach to support preventative implant care, surgical planning and cost-efficient treatment, which are key concerns for both clinicians and care organizations. It's a strong example of how SimplyTest equips providers with timely insights that improve patient outcomes and help reduce avoidable expenses.'
Healthcare professionals can learn more about the IMPLANT offering and request materials at https://www.simplytest.solutions.
About SimplyTest
SimplyTest® is redefining the starting point of care through next-generation salivary science. The SimplyTest platform delivers fast, noninvasive screenings that empower health care providers, functional medicine practitioners and dental professionals to detect microbial risks earlier, personalize treatment with precision and connect oral health to whole-body outcomes. Built on the belief that better diagnostics lead to better outcomes, SimplyTest is advancing a smarter, data-driven model of dentistry where early insight is the first step in personalized care. To learn more, visit https://www.simplytest.solutions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
One A Day® Launches First of its Kind Multivitamin Gummy with Iron to Help Fill Nutrient Gaps in Kids
One A Day® Kids Multi with Iron provides 2/3 of the recommended daily value of Iron and is one of three offerings in the new Kids' line WHIPPANY, N.J., July 23, 2025--(BUSINESS WIRE)--One A Day®, the multivitamin and supplement brand rooted in 80+ years of nutritional science, announced the launch of One A Day® Kids Multi with Iron, a gummy multivitamin with 12mg of iron per serving1—no kids multivitamin gummy among leading brands has more iron—to help fill nutrient gaps kids may have. Iron is an essential mineral for healthy growth and development. As picky eating behavior is common according to a new survey sponsored by One A Day®, children may be falling short of important nutrients like iron. The survey sponsored by One A Day® reveals that mealtime can often feel like a standoff for parents and kids, with approximately two-thirds (66%) sharing that their child refuses meals at least once a week and more than half (54%) say their child mostly eats snacks, while refusing full meals. This can make it challenging to help kids get enough of the key nutrients they may need for healthy development and highlights the need for nutritional support during this picky phase. The survey also found that over half (51%) of parents worry their child's eating habits will affect growth and development, with 46% saying that managing their child's eating habits is a top parenting concern – even ahead of screentime. To shed light on the ways that parents can help kids get enough daily nutrients, One A Day® Kids is partnering with Dr. Jessica Andrade, board certified pediatrician. "Through my experience working with children and their families, I know how important good, balanced nutrition is for supporting kids' healthy development," shares Dr. Andrade. "Iron is one of the most common nutritional deficiencies in children, and it is crucial to their development. Adding these vitamin gummies to children's daily routines is a simple and tasty way to help meet daily iron needs, especially when they may lack iron in their diets." One A Day® Kids Multi with Iron is one of three offerings in the new One A Day Kids' line. These easy-to-chew gummy multivitamins are specially formulated with key nutrients for kids to support overall healthy growth and development as well as eye, brain, and immune health. One A Day® Kids Multi with Iron Gummies provides key nutrients and an excellent source of iron with 12mg of iron in two gummies a day – providing ⅔ of the recommended Daily Value for this key nutrient. One A Day® Kids Multi With Probiotic Gummies contains essential nutrients, and a probiotic clinically tested in kids. It includes 1 billion CFUs of Bacillus Subtilis DE111® probiotic per serving (2 gummies) to support gut health. One A Day® Kids Multi Gummies is formulated with 9 key vitamins and minerals, offering nutritional support in delicious natural fruit flavors orange, raspberry, and cherry2. "As a brand dedicated to providing consumers with nutritional support at important life stages, we know how important it is for parents to have a trusted multivitamin that kids actually want to take because they like the taste and texture. That's why we are excited to introduce the new One A Day® Kids line including the first of its kind gummy multivitamin with iron for kids," says Lisa Perez, mom of three and General Manager Nutritionals at Bayer, the maker of One A Day®. One A Day® Kids Gummies are formulated with good stuff parents want, without stuff they don't: free of artificial sweeteners, high fructose corn syrup and egg, fish/crustacean shellfish, and dairy (milk) – making them a great option for helping little ones thrive. With this launch, One A Day® reaffirms its commitment to providing consumers with high-quality multivitamins specially designed for different life stages, genders, ages, or health goals. For more information on One A Day® Kids, visit Benefit claims for One A Day(R) Kids Multi Gummies have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. DE111(R) is a trademark of Deerland Probiotics & Enzymes, Inc. 1 One serving = two gummies 2 Natural orange, raspberry and cherry flavors with other natural flavors Research MethodologyBayer sponsored an online survey for One A Day® Vitamins from 3/19/2025 to 3/23/2025 to explore how pickiness manifests in children and understand the real-life impact it has on parents. The survey included 1,000 U.S. adults with children ages 4-10 years old, balanced by gender and region to reflect U.S. census demographics. About One A Day®One A Day is a multivitamin and supplement brand offering specially formulated products for many members of the family. From prenatal to 65+, One A Day offers products for different ages, genders and health goals. The portfolio includes tablet, softgel, capsule, and gummy products. One A Day products are available at most major drug stores and retailers nationwide. About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, "Health for all, Hunger for none," the company's products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. View source version on Contacts Jan SchlegelmilchDirector, Integrated Communications, U.S. Consumer Bryan GibbsVice President, Media, twelvenote agencybgibbs@ Sign in to access your portfolio
Business Wire
18 minutes ago
- Business Wire
Hyperfine Begins Commercial Launch of Optive AI™ Software, Bringing Substantially Improved Image Quality to the Installed Base of Swoop® Systems
GUILFORD, Conn.--(BUSINESS WIRE)-- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced the commercial launch of the Optive AI™ software for existing Swoop® system customers. Optive AI™ software, which also powers the transformative image quality of the next-generation Swoop® system, is now commercially available to customers in the U.S. With over 650 scans under our belt on the previous software, with just a single scan in critical care today after installing Optive AI™ software on the Swoop® system, the difference is crystal clear. Share Optive AI™ software enhances each stage of the imaging process—from noise cancellation and image acquisition to reconstruction and post-processing. The result is brain images with greater clarity, uniformity, and sharper anatomical detail. The FDA cleared Optive AI™ software in late May 2025, and the software is also available for commercial use in Canada, Australia, and New Zealand, with additional international approvals expected later this year. Hyperfine has now begun rolling out the new software to hospitals and outpatient neurology offices in the U.S. with plans to bring this imaging software to all current customers in the coming weeks. Jennifer Villa Frabizzio, MD, Chief of Neuroradiology, Jefferson Abington Hospital, noted, 'With over 650 scans under our belt on the previous software, with just a single scan in critical care today after installing Optive AI™ software on the Swoop® system, the difference is crystal clear. FLAIR images, especially, show markedly improved resolution and are 40 seconds faster. Kudos to Hyperfine engineers for this large leap.' Chetan Shah, MD, Chair, Pediatric Radiology, Wolfson Children's Hospital, noted, 'This upgrade is a true game changer for MRI technology—an overnight leap in image quality that's rarely seen. Portable MRI can now extend beyond the ICU to serve ER patients and outpatients—a breakthrough in every sense.' Optive AI™ software is fully compatible with first-generation Swoop® systems and requires no hardware modifications, enabling current users to immediately benefit from next-generation image quality. The new software supports a wide range of patient populations, as well as various clinical use cases in emergency, intensive care, and neurology office settings. 'We're thrilled to bring the power of Optive AI™ software to our current customers,' said Maria Sainz, President and CEO of Hyperfine. 'This is more than a software update—it's a milestone that reflects our commitment to sustained innovation, improved clinical performance, and driving the adoption of portable brain MRI across multiple sites of care. We are incredibly pleased with the feedback from the initial cases of patients scanned with the Optive AI™ software and look forward to broadening clinical utility with this high level of image quality for patients in different care settings inside and outside of the hospital.' For more information about the Swoop® system and Optive AI™ software, please visit About the Swoop® Portable MRI Systems The Swoop® Portable MR Imaging® Systems are U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. They are portable, ultra-low-field magnetic resonance imaging devices for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. About Hyperfine, Inc. Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. The Swoop logo, Optive AI logo, and Optive AI are trademarks of Hyperfine, Inc. Forward-Looking Statements This press release includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the 'Company') may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as 'expect,' 'estimate,' 'project,' 'budget,' 'forecast,' 'anticipate,' 'intend,' 'plan,' 'may,' 'will,' 'could,' 'should,' 'believes,' 'predicts,' 'potential,' 'continue,' and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's goals and commercial plans, the benefits of the Company's products and services, and the Company's future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company's product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock on the Nasdaq; the Company's inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services and reimbursement for medical procedures conducted using the Company's products and services; the Company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in Company's filings with the Securities and Exchange Commission, including those under 'Risk Factors' therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
Business Wire
18 minutes ago
- Business Wire
Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial
DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage oncology company leveraging its proprietary RADR® artificial intelligence (AI) platform to systematically transform drug discovery paradigms, today announces that a heavily pretreated patient with aggressive Grade 3 non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL) achieved a complete metabolic response in the ongoing Phase 1 clinical trial of LP-284. This represents the first complete response observed with LP-284 and displays profound clinical activity in one of the most therapeutically challenging hematologic cancers. This extraordinary clinical observation represents a transformative moment for our computationally guided, therapeutic development paradigm Share The RADR®-driven, AI approach enables Lantern to rapidly determine mechanisms of action of any cancer focused molecule, identify biomarker-driven subpopulations and optimize combination strategies for the clinical setting. The 41-year-old patient had previously failed three aggressive treatment regimens over 18 months over the last 15 months. These included: standard R-CHOP/Pola-R-CHP chemotherapy, CAR-T cell therapy (liso-cel), and CD3xCD20 bispecific antibody therapy (glofitamab). Following enrollment in April 2025, the patient achieved complete metabolic response with non-avid lesions after completing just two 28-day cycles of LP-284 administered on days one, eight, and 15. This remarkable clinical outcome supports LP-284's synthetic lethal mechanism and is an initial step towards a potential new paradigm for treating refractory aggressive lymphomas and B-cell malignancies. Paradigm-Shifting Observation of Complete Response in Therapeutically Exhausted Patient 'This extraordinary clinical observation represents a transformative moment for our computationally guided, therapeutic development paradigm,' said Panna Sharma, President and CEO of Lantern Pharma. 'Our RADR® platform's systematic analysis of molecular vulnerabilities enabled us to rapidly advance LP-284 from computational concept to a clinical milestone in a patient in under three years at approximately $3 million — demonstrating how AI-driven precision has the promise to fundamentally reshape pharmaceutical innovation. This complete metabolic response in a patient who had exhausted all conventional therapeutic options strongly supports our strategic thesis that computational approaches can unlock previously inaccessible therapeutic opportunities.' LP-284, a computationally optimized next-generation acylfulvene, was systematically developed with guidance from Lantern's RADR® platform to exploit synthetic lethal interactions in cancer cells harboring specific DNA damage repair deficiencies. The compound represents a fundamentally different therapeutic strategy with the potential to preferentially target malignant cells while preserving healthy tissue function — a precision approach aimed at delivering transformative clinical benefit for patients who have failed multiple prior treatment modalities. Potential to Address a Critical Therapeutic Void in Refractory DLBCL This patient's clinical journey exemplifies the devastating trajectory of aggressive DLBCL in the refractory setting. Despite achieving an initial complete metabolic response with CAR-T therapy (liso-cel) at day 30, the patient experienced disease progression by day 90. Subsequent treatment with the CD3xCD20 bispecific antibody glofitamab resulted in progressive disease with multifocal new lesions. At study entry on the LP-284-Phase 1 trial in April 2025, the patient presented with extensive multifocal bony lesions across thoracic and lumbar spine locations and hips — representing an extremely challenging clinical scenario. The achievement of complete metabolic response with non-avid lesions following just two cycles of LP-284 therapy represents a potential future paradigm-shifting alternative for treating therapeutically exhausted DLBCL patients. This encouraging outcome underscores LP-284's potential to address critical gaps in the therapeutic armamentarium for patients who have failed both conventional and cutting-edge immunotherapeutic approaches. Advancing Strategic Clinical Development and Global Expansion The complete metabolic response achievement positions LP-284 for accelerated development pathways and strengthens Lantern's strategic position in the competitive hematologic oncology landscape. This clinical milestone provides important confirmation of the company's systematic approach to therapeutic development and creates additional opportunities for international partnership expansion and collaborative research initiatives. Lantern's ongoing Phase 1 dose-escalation study (NCT06132503) is designed to evaluate LP-284's safety profile, optimal dosing parameters, and preliminary efficacy signals across multiple aggressive lymphoma subtypes. The trial's systematic design enables precise evaluation of LP-284's therapeutic potential across genetically defined patient populations, with a current focus on aggressive NHL subtypes including mantle cell lymphoma and high-grade B-cell lymphomas. LP-284's multiple FDA Orphan Drug Designations position the compound for potential expedited regulatory pathways and enhanced market exclusivity frameworks. Transforming Global Oncology Through Computational Precision This clinical development provides important confirmation of the transformative potential of Lantern's RADR® platform, which leverages over 200 billion oncology-focused data points and 200+ machine learning algorithms to assist in systematically identifying and optimizing therapeutic opportunities. The platform's computational efficiency enabled Lantern to rapidly advance the LP-284's program into the clinic in under three years at a cost of approximately $3 million — representing striking development efficiency compared to traditional pharmaceutical paradigms. The complete metabolic response achievement positions LP-284 to seek a future role within a global blood cancer market focused on B-cell cancer that is estimated at $4 billion annually, with DLBCL representing the largest aggressive lymphoma subtype affecting approximately 200,000 patients globally each year. The critical unmet need in refractory/relapsed settings represents a substantial commercial opportunity for innovative therapeutic approaches that can deliver meaningful clinical benefit to therapeutically exhausted patient populations. Next Steps and Future Development Lantern plans to continue enrollment in the Phase 1 trial while closely monitoring the responding patient and other potential future patients for durability of response and efficacy signals. The company anticipates providing additional clinical updates as the trial progresses and more patients reach evaluable timepoints. The complete response achievement positions LP-284 for potential accelerated development pathways and creates opportunities for strategic partnerships as Lantern advances its synthetic lethal portfolio toward later-stage clinical trials. About LP-284 LP-284 is an investigational next-generation acylfulvene designed to exploit synthetic lethal interactions in cancer cells with DNA damage repair deficiencies. Developed with guidance from Lantern's AI platform RADR®, LP-284 represents a novel therapeutic approach with potential to address critical gaps in the treatment of relapsed or refractory non-Hodgkin's lymphoma and other hematologic malignancies. The compound is currently being evaluated in a Phase 1 clinical trial (NCT06132503) to determine its safety profile, optimal dosing, and potential activity in patients with aggressive NHL subtypes who have failed standard therapies. LP-284 has received multiple Orphan Drug Designations from the U.S. Food and Drug Administration, including designations for mantle cell lymphoma and high-grade B-cell lymphomas, recognizing its potential to address significant unmet medical needs in rare cancer populations. About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is an AI-driven biotechnology company focused on accelerating and optimizing the discovery, development, and commercialization of cancer therapies. Its proprietary RADR® platform leverages artificial intelligence and machine learning with the aim of uncovering novel therapeutic opportunities, accelerating drug development timelines, and improving patient outcomes. The company's approach combines advanced computational biology with traditional pharmaceutical development to transform how cancer drugs are discovered and developed. For more information, visit: - Website: ( - LinkedIn: - X: @lanternpharma ( Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR ® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR ® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "model," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned clinical trials and operations, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that our research and the research of our collaborators may not be successful, (iv) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the risk that no drug product based on our proprietary RADR ® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vii) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on March 27, 2025. You may access our Annual Report on Form 10-K for the year ended December 31, 2024, under the investor SEC filings tab of our website at ( or on the SEC's website at ( Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.
